Compare TG Therapeutics Inc (TGTX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wells Fargo & Co — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Wells Fargo & Co trades at $87.9 (market cap $261.45B). The key difference: Wells Fargo & Co is far larger — about 31.7× TG Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WFC | |
|---|---|---|
Market Cap | $8.26B | $261.45B |
Sector | Health | Financials |
52-Week High | $59.06 | $96.40 |
52-Week Low | $26.39 | $73.42 |
Enterprise Value | $8.50B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wells Fargo (WFC) trades at $87.75, up 0.26% today, with a neutral technical signal and bullish moving averages. The stock shows improving fundamentals with 2025 revenue of $83.70B and net income of $21.34B, yielding a 25.97% net margin. Recent Q2 2026 earnings beat expectations with EPS of $1.96 versus $1.73 expected. Analyst consensus is mixed with a $97.36 price target, suggesting 11% upside. The bank continues growth initiatives post-asset cap removal, though net cash flow remains negative.
Outlook remains cautiously optimistic given valuation support (P/E 12.55) and dividend yield, but risks include net interest margin pressure and volatile cash flows. Institutional activity is mixed with some trimming positions. Earnings sustainability and loan growth execution are key catalysts for further upside, while macroeconomic sensitivity poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
